In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche/Genentech Partnering Team: One Face For The World To See

An Interview With Roche Pharma Partnering Head For Neuroscience, Ophthalmology And Rare Diseases

Executive Summary

Thomas Zioncheck, global head of neuroscience, ophthalmology and rare diseases, Roche Pharma Partnering, talks to In Vivo about Roche and Genentech’s united partnering group, 2019 successes, and highlights ahead for the big pharma’s neuroscience pipeline.

You may also be interested in...



Roche Partnering Casts Wide Net To Expand Company’s Neuroscience Pipeline

Roche completed 80 significant deals in 2019, neuroscience partnering head Tom Zioncheck said, many of which helped the company build its growing pipeline in neurological diseases.

In Vivo’s Deals Of The Year 2020: Cast Your Vote!

It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

Deals Shaping The Medical Industry, December 2020

Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2020. Data provided by Biomedtracker

Topics

Related Companies

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel